DRI Healthcare Trust

DHT.U

CA23344H1091

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 03:59:59 2024-04-26 pm EDT			5-day change	1st Jan Change
16.36 ^CAD	-1.09%		-2.85%	+31.09%

Apr. 23	DRI Healthcare Trust Brief: Adds Transaction "Significantly" Reduces Potential Dilution With a Net Reduction of Warrants Equivalent to 8.2% of Units Outstanding	MT
Apr. 23	DRI Healthcare Trust Brief: Says Closed Prior Announced Refinancing of Preferred Securities	MT

DRI Healthcare Trust Declares Quarterly Cash Distribution for the First Quarter of 2024, Payable on April 19, 2024

February 28, 2024 at 05:31 pm EST

DRI Healthcare Trusty that its board of trustees has declared an increased quarterly cash distribution in the amount of USD 0.085 per unit for the first quarter of 2024, payable on April 19, 2024, to unitholders of record as of March 31, 2024.

Latest news about DRI Healthcare Trust

DRI Healthcare Trust Brief: Adds Transaction "Significantly" Reduces Potential Dilution With a Net Reduction of Warrants Equivalent to 8.2% of Units Outstanding	Apr. 23	MT
DRI Healthcare Trust Brief: Says Closed Prior Announced Refinancing of Preferred Securities	Apr. 23	MT
DRI Healthcare Trust Refinances Preferred Securities	Apr. 15	MT
DRI Healthcare Trust Seeks Acquisitions	Feb. 29	CI
Transcript : DRI Healthcare Trust, Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
DRI Healthcare Trust Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
DRI Healthcare Trust Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Tranche Update on DRI Healthcare Trust (TSX:DHT.UN)'s Equity Buyback Plan announced on November 13, 2023.	Feb. 28	CI
National Bank Raises DRI Healthcare Target to $22 on Omidria News, Guidance Increase	Feb. 01	MT
DRI Healthcare Trust Expands Royalty Entitlement on US Net Sales of Omidria, Updates Deployment and CAGR Guidance	Feb. 01	MT
DRI Healthcare Trust Brief: Announcing Expansion of its Royalty Entitlement on the US Net Sales of Omidria), Updating Deployment and CAGR Guidance	Feb. 01	MT
National Bank Highlights Key Takeaways From DRI Healthcare Trust's Investor Meetings; Raises Price Target	Dec. 22	MT
Transcript : DRI Healthcare Trust, Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
DRI Healthcare Trust Swings to a Loss in the Third Quarter	Nov. 13	MT
DRI Healthcare Trust Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
DRI Healthcare Trust's Equity Buyback announced on November 7, 2022, has closed with 11,236,113 shares, for $6.57 million.	Nov. 13	CI
Tranche Update on DRI Healthcare Trust (TSX:DHT.UN)'s Equity Buyback Plan announced on November 7, 2022.	Nov. 13	CI
Tranche Update on DRI Healthcare Trust (TSX:DHT.UN)'s Equity Buyback Plan announced on November 7, 2022.	Nov. 13	CI
DRI Healthcare Trust (TSX:DHT.UN) announces an Equity Buyback for 3,280,195 shares, representing 5.82% of its issued share capital.	Nov. 13	CI
DRI Healthcare Trust authorizes a Buyback Plan.	Nov. 13	CI
DRI Healthcare Trust Announces Upsized $500 Million Credit Facilities	23-10-31	CI
DRI Healthcare Trust Announcing Upsized US$500 Million Credit Facilities	23-10-31	MT
DRI Healthcare Trust Brief: Says Move "Significantly enhances deployment capacity without increasing leverage parameters"	23-10-31	MT
DRI Healthcare Trust Brief: Announcing Upsized US$500 Million Credit Facilities	23-10-31	MT
National Bank on DRI Healthcare Trust --Equity Financing To Fund New Royalties	23-09-21	MT

Chart DRI Healthcare Trust

Duration

Period

More charts

Company Profile

DRI Healthcare Trust is a Canada-based company, which is engaged in providing financing to advance innovation in the life sciences industry. The Company is involved in pharmaceutical royalty monetization and provides capital to inventors, academic institutions and biopharma companies. It is acquiring approximately 70 royalties on 40-plus drugs, including Eylea, Spinraza, Zytiga, Remicade, Keytruda and Stelara. The Companyâs portfolio includes Empaveli, Eylea, Natpara, Omidria, Rydapt, Simponi, Syfovre, Vonjo, Zejula and Zytiga. Its therapeutic areas include influenza, endocrinology, ophthalmology, dermatology, oncology, neurology, autoimmune diseases, heme-onc, lysosomal storage disorder, respiratory diseases, oncology and others. The Company is managed by DRI Capital Inc. Its products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Takeda; Galderma Laboratories; Novartis; Biogen; CTI Biopharma; Roche, Novartis, Johnson & Johnson, and others.

Sector

Pharmaceuticals

Calendar

2024-05-05 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for DRI Healthcare Trust

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.95 USD

Average target price

15.3 USD

Spread / Average Target

+28.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DRI HEALTHCARE TRUST	+31.09%	674M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals